• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Mesoblast Limited (Amendment)

    9/6/23 6:42:49 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MESO alert in real time by email
    SC 13G/A 1 ea184730-13ga1george_meso.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Mesoblast Limited

    (Name of Issuer)

     

    Ordinary Shares

    (Title of Class of Securities)

     

    590717104

    (CUSIP Number)

     

    See Item 2(b) below

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    24 August 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 590717104   13G   Page 1 of 9 Pages

     

    1.  

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Gregory George

     

    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)    ☐

    (b)    ☒

    3.  

    SEC USE ONLY

     

    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    29,049,805

     
    6.

    SHARED VOTING POWER

     

    44,147,597

     
    7.

    SOLE DISPOSITIVE POWER

     

    29,049,805

     
    8.

    SHARED DISPOSITIVE POWER

     

    44,147,597

     
               
    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    73,197,402

    10.  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions)    ☐

     

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.99%

    12.  

    TYPE OF REPORTING PERSON (see instructions)

     

    IN

     

     

     

     

    CUSIP No. 590717104   13G   Page 2 of 9 Pages

     

    1.  

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    James George

     

    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)    ☐

    (b)    ☒

    3.  

    SEC USE ONLY

     

    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    2,500,000

     
    7.

    SOLE DISPOSITIVE POWER

     

    0

     
    8.

    SHARED DISPOSITIVE POWER

     

    2,500,000

     
               
    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,500,000

    10.  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions)    ☐

     

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.31%

    12.  

    TYPE OF REPORTING PERSON (see instructions)

     

    IN

     

     

     

     

    CUSIP No. 590717104   13G   Page 3 of 9 Pages

     

    1.  

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Grant George

     

    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)    ☐

    (b)    ☒

    3.  

    SEC USE ONLY

     

    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    2,355,000

     
    7.

    SOLE DISPOSITIVE POWER

     

    0

     
    8.

    SHARED DISPOSITIVE POWER

     

    2,355,000

     
               
    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,355,000

    10.  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions)    ☐

     

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.29%

    12.  

    TYPE OF REPORTING PERSON (see instructions)

     

    IN

     

     

     

     

    CUSIP No. 590717104   13G   Page 4 of 9 Pages

     

    1.  

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    G to the Fourth Investments, LLC

     

    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)    ☐

    (b)    ☒

    3.  

    SEC USE ONLY

     

    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Nevada

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    39,242,597

     
    7.

    SOLE DISPOSITIVE POWER

     

    0

     
    8.

    SHARED DISPOSITIVE POWER

     

    39,242,597

     
               
    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    39,242,597

    10.  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions)    ☐

     

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.82%

    12.  

    TYPE OF REPORTING PERSON (see instructions)

     

    OO

     

     

     

     

    CUSIP No. 590717104   13G   Page 5 of 9 Pages

     

    Item 1.

     

    (a)

    Name of Issuer

         
        Mesoblast Limited
         
      (b)

    Address of Issuer’s Principal Executive Offices

         
        Level 38, 55 Collins Street, Melbourne 3000, Australia

     

    Item 2.

     

    (a)

    Name of Person Filing

         
        Gregory George, James George, Grant George and G to the Fourth Investments, LLC (the “Reporting Persons”)
         
      (b)

    Address of the Principal Office or, if none, residence:

         
       

    The principal business office of the Reporting Persons is:

     

    Gregory George

    371 Channelside Walkway

    PH 1702, Tampa

    Florida, 33602

     

    G to the Fourth Investments, LLC

    831 Laca Street

    Dayton

    Nevada, 89403

     

    James George

    371 Channelside Walkway

    PH 1702, Tampa

    Florida, 33602

     

    Grant George

    371 Channelside Walkway

    PH 1702, Tampa

    Florida, 33602

     

      (c)

    Citizenship

         
       

    Gregory George, James George and Grant George are U.S. citizens.

    G to the Fourth Investments, LLC, is organized in Nevada

         
      (d)

    Title of Class of Securities

         
       

    Ordinary Shares / American Depositary Receipts

         
      (e)

    CUSIP Number

         
        590717104

     

     

     

     

    CUSIP No. 590717104   13G   Page 6 of 9 Pages

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not Applicable

     

    Item 4. Ownership.

     

    The ownership information below represents beneficial ownership of ordinary shares as represented by American Depositary Receipts by the Reporting Persons as of August 24, 2023, based upon 814,204,825 ordinary shares of the issuer outstanding as of August 24, 2023.

     

    Gregory George is the sole beneficial owner of 29,049,805 ordinary shares, which include 6,830,602 ordinary shares underlying warrants and 22,205,910 ordinary shares held in the form of American Depositary Receipts (“ADRs”).

     

    Gregory George is a member of G to the Fourth Investments, LLC and has discretionary authority to vote and dispose of 39,242,597 ordinary shares held by G to the Fourth Investments, LLC. Gregory George may be deemed to be the beneficial owner of these shares.

     

    Gregory George has discretionary authority to vote and dispose of 2,500,000 ordinary shares held in the form of ADRs by his son James George. Gregory George may be deemed to be the beneficial owner of these shares.

     

    Gregory George has discretionary authority to vote and dispose of 2,405,000 ordinary shares held in the form of ADRs by his son Grant George. Gregory George may be deemed to be the beneficial owner of these shares.

     

    Gregory George

     

      a) Amount beneficially owned: 73,197,402

     

      b) Percent of class: 8.99%

     

      c) Number of shares as to which the person has:

     

      i. Sole power to vote or to direct the vote: 29,049,805

     

      ii. Shared power to vote or to direct the vote: 44,147,597

     

      iii. Sole power to dispose or to direct the disposition of: 29,049,805

     

      iv. Shared power to dispose or to direct the disposition of: 44,147,597

     

     

     

     

    CUSIP No. 590717104   13G   Page 7 of 9 Pages

     

    James George

     

      a) Amount beneficially owned: 2,500,000

     

      b) Percent of class: 0.31%

     

      c) Number of shares as to which the person has:

     

      i. Sole power to vote or to direct the vote: 0

     

      ii. Shared power to vote or to direct the vote: 2,500,000

     

      iii. Sole power to dispose or to direct the disposition of: 0

     

      iv. Shared power to dispose or to direct the disposition of: 2,500,000

     

    Grant George

     

      a) Amount beneficially owned: 2,355,000

     

      b) Percent of class: 0.29%

     

      c) Number of shares as to which the person has:

     

      i. Sole power to vote or to direct the vote: 0

     

      ii. Shared power to vote or to direct the vote: 2,355,000

     

      iii. Sole power to dispose or to direct the disposition of: 0

     

      iv. Shared power to dispose or to direct the disposition of: 2,355,000

     

    G to the Fourth Investments, LLC

     

      a) Amount beneficially owned: 32,284,567

     

      b) Percent of class: 4.82%

     

      c) Number of shares as to which the person has:

     

      i. Sole power to vote or to direct the vote: 0

     

      ii. Shared power to vote or to direct the vote: 39,242,597

     

      iii. Sole power to dispose or to direct the disposition of: 0

     

      iv. Shared power to dispose or to direct the disposition of: 39,242,597

     

     

     

     

    CUSIP No. 590717104   13G   Page 8 of 9 Pages

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10. Certification.

     

      (a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
         
      (b) The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No. 590717104   13G   Page 9 of 9 Pages

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    September 6, 2023 /s/ Gregory George
      Signature
       
      Gregory George
      Name
       
    September 6, 2023 /s/ James George
      Signature
       
      James George
      Name
       
    September 6, 2023 /s/ Grant George
      Signature
       
      Grant George
      Name
       
    September 6, 2023 /s/ Gregory George
      Signature
       
      G to the Fourth Investments, LLC
       
      Gregory George
      Name
       
      Manager
      Title

     

     

    Get the next $MESO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MESO

    DatePrice TargetRatingAnalyst
    12/23/2024Buy → Hold
    Jefferies
    9/24/2024$12.00Hold → Buy
    Maxim Group
    8/29/2024Hold → Buy
    Jefferies
    7/23/2024$4.00 → $11.00Neutral → Overweight
    Piper Sandler
    8/31/2023Hold → Buy
    Jefferies
    8/7/2023Buy → Hold
    Maxim Group
    8/4/2023$7.00 → $2.00Overweight → Neutral
    Piper Sandler
    8/4/2023Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $MESO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

      NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years of orphan-drug exclusive approval from U.S. Food and Drug Administration (FDA) for Ryoncil® (remestemcel-L) for treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older. This period of statutory exclusivity means that the FDA will not approve another mesenchymal stromal or stem cell (MSC) products for this indication during the 7-year period from the approval of Ryoncil®. Separately, Mesoblast has biologic exclusivity prev

      5/14/25 10:57:06 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

      NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025. "We were very pleased to have made Ryoncil® (remestemcel-L) commercially available to treat children with acute GVHD within one quarter of receiving FDA approval as the first mesenchymal stromal cell (MSC) therapy approved in the US for any indication," said Dr. Silviu Itescu, CEO of Mesoblast. "With our strong cash position we are well placed to expand Ryoncil® indications to other serious and life-threatening pediatric inflammatory di

      4/29/25 8:53:27 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

      NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. Ms. Cobley has been a global leader in the financial services industry with over 30 years' experience in senior positions at international and domestic banks. Ms. Cobley has served as CEO of Westpac Institutional Bank, Group Treasurer of Commonwealth Bank of Australia, and held senior roles at Barclays Capital and Citibank Limited. Ms. Cobley is currently a director of Commonwealth Bank of Australia, is a member of Chief Executive Women, a member of the Macquarie

      4/28/25 7:44:18 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MESO
    Leadership Updates

    Live Leadership Updates

    See more
    • Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

      NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025. "We were very pleased to have made Ryoncil® (remestemcel-L) commercially available to treat children with acute GVHD within one quarter of receiving FDA approval as the first mesenchymal stromal cell (MSC) therapy approved in the US for any indication," said Dr. Silviu Itescu, CEO of Mesoblast. "With our strong cash position we are well placed to expand Ryoncil® indications to other serious and life-threatening pediatric inflammatory di

      4/29/25 8:53:27 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

      NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. Ms. Cobley has been a global leader in the financial services industry with over 30 years' experience in senior positions at international and domestic banks. Ms. Cobley has served as CEO of Westpac Institutional Bank, Group Treasurer of Commonwealth Bank of Australia, and held senior roles at Barclays Capital and Citibank Limited. Ms. Cobley is currently a director of Commonwealth Bank of Australia, is a member of Chief Executive Women, a member of the Macquarie

      4/28/25 7:44:18 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dr. Gregory George MD PhD Joins Mesoblast Board

      NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Dr. Gregory George MD PhD, Mesoblast's largest shareholder, to its Board of Directors. Dr. George founded and managed the largest privately owned ambulatory surgical center company in the United States, SurgCenter Development. Dr. George brings to the Board his background as a medical scientist with unique operational experience having built a start-up company in the medical field and turning it into a highly-efficient multi-billion-dollar commercial organization. Mesoblast Founder and Chief

      2/23/25 6:33:52 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MESO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mesoblast downgraded by Jefferies

      Jefferies downgraded Mesoblast from Buy to Hold

      12/23/24 7:24:07 AM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mesoblast upgraded by Maxim Group with a new price target

      Maxim Group upgraded Mesoblast from Hold to Buy and set a new price target of $12.00

      9/24/24 8:11:34 AM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mesoblast upgraded by Jefferies

      Jefferies upgraded Mesoblast from Hold to Buy

      8/29/24 7:56:03 AM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MESO
    Financials

    Live finance-specific insights

    See more
    • Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

      NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended June 30, 2024. Mesoblast Chief Executive Silviu Itescu said: "During the past year we have built significant momentum in our interactions with the United States Food and Drug Administration (FDA) across each of our Phase 3 products. I am very pleased that our Biologics License Application (BLA) resubmission for approval of Ryoncil® (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD)

      8/28/24 7:27:43 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

      NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended December 31, 2023. Mesoblast Chief Executive Silviu Itescu said: "We were very busy operationally during the last quarter and continued to have positive engagement with the United States Food and Drug Administration (FDA) across our lead programs. We have strengthened our balance sheet while maintaining overall spending constraint in line with our corporate objectives. For our product Ryoncil® (remestemcel-L) for life-threatening steroid-ref

      2/28/24 5:57:09 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023

      NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and an operational update for the period ended June 30, 2023, and provided an overview of upcoming milestones. Mesoblast Chief Executive Silviu Itescu said: "We had anticipated that remestemcel-L would have been approved by the United States Food and Drug Administration (FDA) for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD), a condition with a high mortality where there are no approved therapies for children under 12 years old. During the six-month B

      8/30/23 7:07:02 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MESO
    SEC Filings

    See more
    • SEC Form 6-K filed by Mesoblast Limited

      6-K - MESOBLAST LTD (0001345099) (Filer)

      5/14/25 8:46:57 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Mesoblast Limited

      6-K - MESOBLAST LTD (0001345099) (Filer)

      4/29/25 9:39:45 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Mesoblast Limited

      6-K - MESOBLAST LTD (0001345099) (Filer)

      4/29/25 7:13:53 AM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MESO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

      SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

      12/16/24 12:08:07 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

      SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

      10/9/24 3:42:14 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

      SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

      7/11/24 7:38:31 AM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care